12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PV-10: Additional Phase II data

Additional data from the open-label, U.S. and Australian Phase II PV-10-MM-02 trial in 80 patients with stage III or IV metastatic melanoma who were treated with intralesional PV-10 showed that patients with stage III disease had greater mean PFS (9.7 vs. 3.1 months) and OS (12.6 vs. 7.3 months) vs. patients with stage...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >